GoldenGolden
PhagoMed Biopharma

PhagoMed Biopharma

A biotechnology company developing phage therapies to replace ineffective antibiotics.

All edits

Edits on 13 Aug, 2020
Lax Mariappan
Lax Mariappan edited on 13 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Founded date
November 23, 2017
Edits on 4 Aug, 2020
Marie Gabrielle Laguna- Bedia
Marie Gabrielle Laguna- Bedia edited on 4 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
CEO
Lorenzo Corsini
Edits on 1 Aug, 2020
Golden AI"Funding autocalculation"
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1/-1 properties)
Infobox
Total funding amount (USD)
4,720,000
Total funding amount (USD)
6,400,000
Golden AI
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Golden AI"Funding autocalculation"
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Total funding amount (USD)
4,720,000
Golden AI
Golden AI edited on 1 Aug, 2020
Edits made to:
Infobox (+1 properties)
Edits on 30 Jul, 2020
Lax Mariappan
Lax Mariappan edited on 30 Jul, 2020
Edits made to:
Infobox (+1 properties)
Infobox
Edits on 11 Apr, 2019
Dawson Sewell
Dawson Sewell approved a suggestion from Golden's AI on 11 Apr, 2019
Edits made to:
Article (+13/-13 characters)
Article

PM398 is a phage therapyphage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).

Edits on 4 Apr, 2019
Dawson Sewell
Dawson Sewell edited on 4 Apr, 2019
Edits made to:
Infobox (+11 properties)
Description (+87 characters)
Article (+2 videos) (+549 characters)
Documentaries, videos and podcasts (+3 rows) (+9 cells) (+328 characters)
Categories (+1 topics)
Related Topics (+1 topics)
Topic thumbnail

PhagoMed Biopharma

A biotechnology company developing phage therapies to replace ineffective antibiotics.

Article

PhagoMed Biopharma is a biotechnology company developing phage therapies to replace ineffective antibiotics that is headquartered in Vienna, Austria and was founded in 2017 by Alexander Belcredi and Burkhard Wippermann.

Products
PM398

PM398 is a phage therapy designed to destroy multi-drug resistant methicillin-resistant Staphylococcus aureus (MRSA).

...
Funding
Seed

On August 28, 2018 PhagoMed Biopharma completed a seed funding round with €4M in funding from from undisclosed investors.

Documentaries, videos and podcasts

Title
Date
Link

PhagoMed - Virtual Tour (aws Phoenix video in English)

February 13, 2019

PhagoMed Biopharma uses technology to find alternative to antibiotics

January 8, 2019

PhagoMed PM398 in action

November 13, 2018

Infobox
Categories
Related Topics
Edits on 21 Jan, 2019
Meredith Hanel"Initial topic creation"
Meredith Hanel created this topic on 21 Jan, 2019
Edits made to:
Topic thumbnail

 PhagoMed Biopharma

A biotechnology company developing phage therapies to replace ineffective antibiotics.

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.